• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >Olanzapine in the treatment of apathy in previously depressed participants maintained with selective serotonin reuptake inhibitors: an open-label, flexible-dose study.
【24h】

Olanzapine in the treatment of apathy in previously depressed participants maintained with selective serotonin reuptake inhibitors: an open-label, flexible-dose study.

机译：奥氮平对先前抑郁的参与者的冷漠治疗采用选择性5-羟色胺再摄取抑制剂维持：一项开放性，灵活剂量研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: We report a clinical trial of olanzapine in the treatment of prominent apathy in the absence of depression in patients on long-term treatment with selective serotonin reuptake inhibitors (SSRIs) for nonpsychotic major depression. METHOD: Participants were 21 men and women who met DSM-IV criteria for major depressive disorder in full remission (Montgomery-Asberg Depression Rating Scale [MADRS] score < or = 12) who had been taking an SSRI for at least 3 months. Data are presented (last observation carried forward) based on 20 enrolled participants who completed at least 1 follow-up visit. Participants had significant symptoms of apathy, defined as a Clinical Global Impressions-Severity of Illness scale (CGI-S) score > or = 3, an Apathy Evaluation Scale (AES) score > 30, and a MADRS item 8 (inability to feel) score > or = 2. Participants with a personal or family history of psychosis were excluded. Olanzapine was titrated in 2.5-mg increments at weekly intervals, until CGI-S score improved > or = 2 points from baseline or > or = 1 point with dose-limiting side effects, and participants continued in the protocol for 8 weeks at a stable dose following this improvement. RESULTS: Improvement was clinically evident and demonstrable on all symptom assessments: AES (mean +/- SD change in score = -21.3 +/- 8.7; p < .0001), CGI-S (-2.7 +/- 0.9; p < .0001), MADRS (-5.6 +/- 5.9; p = .001), and MADRS item 8 (-2.2 +/- 1.4; p < .0001). The mean dose of olanzapine was 5.4 +/- 2.8 mg/day. CONCLUSION: These preliminary data suggest that olanzapine may be effective in treating apathy syndrome in nonpsychotic patients taking SSRIs.
机译：背景：我们报告了奥氮平治疗非精神病性重度抑郁症的选择性5-羟色胺再摄取抑制剂（SSRIs）长期治疗在不存在抑郁症的患者中无抑郁症的临床研究。方法：参加研究的21名男性和女性，均已达到SSRI至少3个月，且完全缓解时符合重度抑郁症的DSM-IV标准（蒙哥马利-阿斯伯格抑郁量表[MADRS]得分<或= 12）。根据20名已完成至少1次随访的入组受试者的数据进行了报告（最后观察到的结转数据）。参与者有明显的冷漠症状，定义为临床总体印象-疾病严重程度评分（CGI-S）得分>或= 3，冷漠评估量表（AES）得分> 30，以及MADRS项目8（无感觉）得分>或=2。有个人或家族精神病史的参与者被排除在外。每周间隔以2.5 mg的增量滴定奥氮平，直到CGI-S评分从基线改善>或= 2分或有剂量限制副作用>或= 1分，并且参与者在方案中稳定持续8周剂量随此改善。结果：在所有症状评估中，临床上都有明显改善，并且可以证明：AES（评分的平均+/- SD变化= -21.3 +/- 8.7; p <.0001），CGI-S（-2.7 +/- 0.9; p < .0001），MADRS（-5.6 +/- 5.9; p = .001）和MADRS第8项（-2.2 +/- 1.4; p <.0001）。奥氮平的平均剂量为5.4 +/- 2.8毫克/天。结论：这些初步数据表明，奥氮平可有效治疗服用SSRIs的非精神病患者的冷漠综合征。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号